ICH Guidelines
FDA Tests
- Monoclonal antibodies are derived by recombinant DNA
- Cell line should follow ICH Q5B & ICH Q5D
- CHO cell line is derived from animals so production should also be subject to ICH Q5A
- Q5A: guidelines concerning “viral safety evaluation of biotechnology products derived from animal cells of human or animal origin.”
- These ICH guidelines were important for establishing the production quality of Herceptin and establishing what the acceptance criteria for each batch would be.
- Identity – is it the right drug as indicated on the label?
- Quantity– how much drug is there and is it consistent with the labeled amount?
- Impurities – are there process impurities or degradation impurities?
- Dissolution – does the active ingredient dissolve out of the dosage unit so that the drug is available for the body to absorb?
ICH Guidelines
Quality Control And Validation
- Active pharmaceutical ingredient in Herceptin is a monoclonal antibody
- Several sections of ICH guidelines are for its development and production
- Monoclonal antibodies should be fully characterized and their binding properties and specifications known
- ICH Q6B lays out what needs to be known about a monoclonal antibody in order to be approved
- Gives “guidance on justifying and setting specifications for proteins and polypeptides”-ICH Q6B
- Guideline states characterization of monoclonal antibody should include: biological activity, purity, impurity, quantity, and immunochemical and physicochemical properties.
Acceptance Criteria for Batch Approval
- Lot retained as reference sample
- Used to for acceptable comparison
- In order to receive COA must match reference sample
- First Herceptin reference sample was Lot HER 1097-3
- Appearance
- color, opalescence, & clarity
- Identity
- correct protein sequence
- Purity
- free of unwanted substances
- Safety
- microbial contaminate free
- Potency
- relative to standard
- Bond Affinity
- strength of monoclonal antibody bonds
- General
- osmolality, pH
Herceptin
Trastuzumab
Trastuzumab
- Trastuzumab produced by CHO cells
- Trastuzumab is a humanized monoclonal antibody
- Binds to HER2 on breast cancer cells
- Human framework region with murine binding regions
- Stops HER2 from signaling cells to grow
Herceptin
- Active substance: trastuzumab
- 150 mg trastuzumab, 3.36mg L - Histidine HCl, 2.16 mg L-Histidine, 136.2mg Trehalose dihydrate, and .6 mg Polysorbate 20
- Finished product a lyophilised powder concentrate
Trastuzumab bound to HER2
Breast Cancer
Symptoms
HER2+ Breast Cancer
- Estimated 231,840 new cases invasive breast cancer to be diagnosed in women in the U.S. in 2015,
- 60,290 new cases of non-invasive breast cancer.
- 2,350 new cases invasive breast cancer expected in men in 2015
- Man’s lifetime risk of breast cancer is about 1 in 1,000
- Breast cancer is the 2nd most commonly diagnosed cancer among American women
- Estimated that about 30% newly diagnosed cancers in women will be breast cancers
•Lumps or masses in the breast
•Swelling part(s) of a breast
•Skin irritation or dimpling
•Breast or nipple pain
•Nipple retraction (inverted nipple)
•Nipple discharge other than when pregnant
HER2+
Trastuzumab HER2 Interaction
- Less sensitive to hormone therapy
- More aggressive because HER2 overproduction stimulates growth
- Immunohistochemistry tests for cell expression levels of the HER2 receptor
-scores 0-3
-HER2+ scores a 3
- Herceptin treats HER2+ Breast Cancer and Stomach Cancer
- 12% of women will develop breast cancer
- 20% of breast cancers are HER2+
- HER2+ is overproduction of Human Epidermal Growth Factor Receptor
Assays
- Potency
- relative to reference standard
- ELISA (Enzyme Linked Immuno Sorbent Assay)
- immunological assay uses enzyme linked labeling
- calculate the potency of the analyte relative to the standard
- Potency approval assures drug has the necessary effects on the body
- Bond Affinity
- strength of antigen - antibody bond
- Radioimmunoassay.
- target antigens have radioactive labels which the monoclonal antibodies bind to
- second antigen is added without radioactive labels
- competition between the two antigens can be used to determine binding affinity.
- Affinity strength of Trastuzumab should be in line with the reference material
- Appearance
- Color, opalescence,& clarity must match reference sample
- Herceptin powder comes as white to pale yellow
- Opalescence and clarity can be assayed using a spectrophotometer
- Identity
- sequence and binding structure
- Peptide Mapping by RP-HPLC
- reverse phase - high performance liquid chromatography
- cleave peptide bonds
- chromatographic separation of the peptides
- analysis done in parallel with the reference
- confirms that no changes to the primary structure have taken place
- MALDI (matrix assisted laser desorption/ionization) Mass Spectrometry
- analyte is put into a crystal matrix which causes the molecules to ionize
- laser then hits the matrix and the energy transfer causes the molecules to enter gas phase
- high electric field, causes it to propel into a flight tube where a detector sequences them
Assays
- Purity
- free of unwanted substances
- PAGE (Polyacrylamide Gel Electrophoresis)
- uses polyacrylamide as the matrix for electrophoresis
- treated with sodium dodecyl in order to make it negative
- stained, purity would be indicated by bands matching those or the reference material
- IEC (ion exchange chromatography)
- rate of passage through the column is determined by particle attraction
- results should match the reference sample
- Safety
- endotoxin, pyrogen, microbe free
- LAL (limulus amebocyte lysate) method
- amebocytes from horseshoe crab blood used to detect pyrogens and endotoxins
- three types of LAL: chromogenic, turbidimetric, gel clot